XE7C Stock Overview
A clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Cardiff Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.50 |
| 52 Week High | US$5.03 |
| 52 Week Low | US$1.82 |
| Beta | 1.8 |
| 1 Month Change | 3.52% |
| 3 Month Change | -38.12% |
| 1 Year Change | -26.58% |
| 3 Year Change | 109.29% |
| 5 Year Change | 34.41% |
| Change since IPO | -99.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| XE7C | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 7.8% | -0.8% | 0.5% |
| 1Y | -26.6% | -12.7% | 14.4% |
Return vs Industry: XE7C underperformed the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: XE7C underperformed the German Market which returned 14.4% over the past year.
Price Volatility
| XE7C volatility | |
|---|---|
| XE7C Average Weekly Movement | 14.3% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: XE7C's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: XE7C's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 33 | Mark Erlander | www.cardiffoncology.com |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC.
Cardiff Oncology, Inc. Fundamentals Summary
| XE7C fundamental statistics | |
|---|---|
| Market cap | €167.12m |
| Earnings (TTM) | -€43.70m |
| Revenue (TTM) | €524.78k |
318.5x
P/S Ratio-3.8x
P/E RatioIs XE7C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XE7C income statement (TTM) | |
|---|---|
| Revenue | US$587.00k |
| Cost of Revenue | US$39.32m |
| Gross Profit | -US$38.73m |
| Other Expenses | US$10.14m |
| Earnings | -US$48.88m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.73 |
| Gross Margin | -6,598.64% |
| Net Profit Margin | -8,326.75% |
| Debt/Equity Ratio | 0% |
How did XE7C perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 14:51 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cardiff Oncology, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sung Ji Nam | Avondale Partners |
| Bryan Brokmeier | Cantor Fitzgerald & Co. |
| Gum-Ming Lowe | Craig-Hallum Capital Group LLC |